Literature DB >> 29199063

Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies.

Patrícia C Pires1, Adriana O Santos2.   

Abstract

The treatment of neurodegenerative and psychiatric disorders remains a challenge in medical research. Several strategies have been developed over the years, either to overcome the blood-brain barrier or to achieve a safer or faster brain delivery, one of them being intranasal (IN) administration. The possibility of direct nose-to-brain transport offers enhanced targeting and reduced systemic side effects. Nevertheless, labile, low soluble, low permeant and/or less potent drugs might need a formulation other than the common solutions or suspensions. For that, the formulation of nanosystems is considered to be a promising approach, since it can protect drugs from chemical and/or metabolic degradation, enhance their solubility, or offer transport through biological membranes. However, the understanding of the factors promoting efficient brain targeting when using nanosystems through the nasal route is currently patchy and incomplete. The main purpose of the present review was to evaluate the association between brain delivery efficacy (in terms of brain targeting, brain bioavailability and time to reach the brain) and nanosystem type. For that, we performed a systematic bibliographic search and analysis. Furthermore, study designs, nanosystem properties, and reporting quality were also analyzed and discussed. It was found a high heterogeneity in how pre-clinical brain targeting studies have been conducted, analyzed and reported in scientific literature, which surely originates a significant degree of bias and data dispersion. This review attempts to provide some systematization recommendations, which may be useful for researchers entering the field, and assist in increasing the uniformity of future reports. The analysis of literature data confirmed that there is evidence of the advantage of the IN route (when compared to the intravenous route) and in using carrier nanosystems (when compared to IN solutions) for brain delivery of a large set of drugs. Among the most represented nanosystem classes, microemulsions had some of the lowest pharmacokinetic ratios values, while polymeric micelles had some of the best. Nevertheless, brain targeting efficacy comparisons between nanosystem groups had little statistical significance, and the superiority of the polymeric micelles group disappeared when nanosystems were compared to the respective IN drug solutions. In fact, some drugs reached the brain so efficiently, even as drug solutions, that further benefit from formulating them into nanosystems became less evident.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Brain targeting; Drug delivery; In vivo; Intranasal; Nanosystem; Pharmacokinetics

Mesh:

Year:  2017        PMID: 29199063     DOI: 10.1016/j.jconrel.2017.11.047

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  24 in total

1.  Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.

Authors:  J H Azambuja; R S Schuh; L R Michels; N E Gelsleichter; L R Beckenkamp; I C Iser; G S Lenz; F H de Oliveira; G Venturin; S Greggio; J C daCosta; M R Wink; J Sevigny; M A Stefani; A M O Battastini; H F Teixeira; E Braganhol
Journal:  Mol Neurobiol       Date:  2019-08-12       Impact factor: 5.590

2.  Superiority of TPGS-loaded micelles in the brain delivery of vinpocetine via administration of thermosensitive intranasal gel.

Authors:  Tarek A Ahmed; Khalid M El-Say; Osama Aa Ahmed; Bader M Aljaeid
Journal:  Int J Nanomedicine       Date:  2019-07-23

Review 3.  Self-Assembled Nanoscale Materials for Neuronal Regeneration: A Focus on BDNF Protein and Nucleic Acid Biotherapeutic Delivery.

Authors:  Yu Wu; Miora Rakotoarisoa; Borislav Angelov; Yuru Deng; Angelina Angelova
Journal:  Nanomaterials (Basel)       Date:  2022-06-30       Impact factor: 5.719

Review 4.  Towards Improvements for Penetrating the Blood-Brain Barrier-Recent Progress from a Material and Pharmaceutical Perspective.

Authors:  Quanguo He; Jun Liu; Jing Liang; Xiaopeng Liu; Wen Li; Zhi Liu; Ziyu Ding; Du Tuo
Journal:  Cells       Date:  2018-03-23       Impact factor: 6.600

5.  Optimization of Curcumin Nanocrystals as Promising Strategy for Nose-to-Brain Delivery Application.

Authors:  Angela Bonaccorso; Maria Rosa Gigliobianco; Rosalia Pellitteri; Debora Santonocito; Claudia Carbone; Piera Di Martino; Giovanni Puglisi; Teresa Musumeci
Journal:  Pharmaceutics       Date:  2020-05-23       Impact factor: 6.321

6.  Formulation Strategies to Improve Nose-to-Brain Delivery of Donepezil.

Authors:  Lupe Carolina Espinoza; Marcelle Silva-Abreu; Beatriz Clares; María José Rodríguez-Lagunas; Lyda Halbaut; María-Alexandra Cañas; Ana Cristina Calpena
Journal:  Pharmaceutics       Date:  2019-02-01       Impact factor: 6.321

Review 7.  Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.

Authors:  Salman Ul Islam; Adeeb Shehzad; Muhammad Bilal Ahmed; Young Sup Lee
Journal:  Molecules       Date:  2020-04-21       Impact factor: 4.411

8.  RVG29-modified microRNA-loaded nanoparticles improve ischemic brain injury by nasal delivery.

Authors:  Rubin Hao; Bixi Sun; Lihua Yang; Chun Ma; Shuling Li
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 9.  Key for crossing the BBB with nanoparticles: the rational design.

Authors:  Sonia M Lombardo; Marc Schneider; Akif E Türeli; Nazende Günday Türeli
Journal:  Beilstein J Nanotechnol       Date:  2020-06-04       Impact factor: 3.649

Review 10.  Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting.

Authors:  Fabio Sonvico; Adryana Clementino; Francesca Buttini; Gaia Colombo; Silvia Pescina; Silvia Stanisçuaski Guterres; Adriana Raffin Pohlmann; Sara Nicoli
Journal:  Pharmaceutics       Date:  2018-03-15       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.